We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.08 | 14.16 | 13.96 | 14.15 | 7,051,252 | 01:00:00 |
From May 2019 to May 2024
By Matteo Castia
Shield Therapeutics PLC said Monday that competitor Teva Pharmaceutical Industries Ltd. has withdrawn all its oppositions against the company's patents.
"Teva has withdrawn both its appeal against the European Patent Office's decision with regard to Shield's patent number 2668175, which covers a 'process for preparing an iron hydroxypyrone' and their opposition with regard to Shield's patent number 3160951 which covers 'crystalline forms of ferric maltol," the pharmaceutical company said.
This means that both patents are maintained and will continue to provide protection, Shield said.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
October 19, 2020 02:59 ET (06:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
